Cancer NetworkOriginal article
<![CDATA[MRD Test Predicts Chemotherapy Survival Benefit in Colorectal Liver Metastases]]>
Data ReadoutpositivePositive
AI Analysis
Summary
A molecular residual disease (MRD) test demonstrated the ability to identify which patients with resected colorectal liver metastases would benefit from adjuvant chemotherapy, suggesting potential for improved patient selection and outcomes.
Outcome Details
MRD test identified patients with resected colorectal liver metastases who gained survival benefit from adjuvant chemotherapy
Importance:5/10
Sentiment:
0.60
colorectal cancerliver metastasesMRD testingadjuvant chemotherapypredictive biomarkeroncology
Read the original article
Published by Cancer Network on July 6, 2026 2:58 PM